Find Out if You Qualify for a Financial Reward by filling out the form below.
Investigation Details
On December 28, 2023, Cytosorbents issued a press release announcing that its pivotal trial investigating the ability of its device candidate, DrugSorb®-ATR, to reduce perioperative bleeding in patients on ticagrelor (Brilinta®, Brilique® – AstraZeneca) undergoing cardiothoracic surgery before completing the recommended washout period, “did not meet the primary effectiveness endpoint in the overall patient population that underwent different types of cardiac surgeries.”
On this news, Cytosorbents’ stock price fell $0.545 per share, or 33.44%, to close at $1.085 per share on December 28, 2023.
| Ticker Symbol | Company Name | Join Deadline | Join |
|---|---|---|---|
| WOLF | Wolfspeed, Inc. | January 17, 2025 | Join |
| SUI | Sun Communities, Inc. | February 10, 2025 | Join |
| SAVA | Cassava Sciences, Inc. | February 10, 2025 | Join |
| APLT | Applied Therapeutics, Inc. | February 18, 2025 | Join |
| BIOA | BioAge Labs, Inc. | March 10, 2025 | Join |
| PCRX | Pacira BioSciences, Inc. | March 14, 2025 | Join |